Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes
Karakus KE, Chesshir L, Walker S, et al.
Diabetologia. Pub. online 15 Jan 2026.
Leggi
Weight regain after cessation of medication for weight management: systematic review and meta-analysis
West S, Scragg J, Aveyard P, et al.
BMJ. Pub. online 7 Jan 2026.
Leggi
FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications: FDA’s evaluation did not identify an increased risk of suicidal ideation or behavior with the use of GLP-1 RA medications
13 gennaio 2026
Leggi
European Commission: Teizeild (Teplizumab) is indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and paediatric patients 8 years of age and older with stage 2 T1D
9 gennaio 2026
Leggi
MiniMed 780G advanced hybrid closed-loop system use during days without user-initiated boluses
Niu F, Liu M, Yovanovich C, et al.
Diabetes Care. Pub. online 7 Jan 2026.
Leggi
Associations of moderate-to-vigorous physical activity timing with type 2 diabetes incidence in UK Biobank and prevalent glycemic measures in NHANES
Feng Q, Albalak G, Ao L, et al.
Diabetes Care. Pub. online 9 Jan 2026.
Leggi
Association between GLP-1 receptor agonists and ischemic optic neuropathy: a meta-analysis
Nogueira A, Rassi TNO, Iqbal A, et al.
Diabetes Care. Pub. online 7 Jan 2026.
Leggi
Effects of lifestyle interventions in pregnancy on gestational diabetes: individual participant data and network meta-analysis
Allotey J, Coomar D, Ensor J, et al.
BMJ. Pub. online 6 Jan 2026.
Leggi
Long-term effects of a multidomain intervention on cognitive function and metabolic control in older adults with type 2 diabetes and mild cognitive impairment: a 42-month follow-up of the J-MIND-Diabetes study
Sugimoto T, Omura T, Araki A, et al.
Diabetes Obes Metab. Pub. online 8 Jan 2026.
Leggi